Foster Wheeler wins Schering-Plough Contract

Foster Wheeler has been awarded an engineering, procurement and construction contract for Phase 2 of Schering-Plough's multi-product active pharmaceutical ingredient plant (MPP2) in Tuas, Singapore.

The $150 million contract will be executed jointly by Foster Wheeler's pharmaceutical centers of excellence in Reading, UK and Singapore.

The plant is a "smart clone" of the MPP1 (multi-product plant) project that Foster Wheeler is currently finishing for Schering-Plough, also in Singapore. The plant will produce the cholesterol-lowering agent, ZETIA(TM) (ezetimibe) Tablets.

Foster Wheeler was awarded two Singapore Ministry of Manpower Gold Awards for the MPP1 project - the first pahse of the multi-product active pharmaceutical ingredient plant. In total, Foster Wheeler has an impressive record of designing and constructing pharmaceutical projects in Singapore, and has achieved 15 million construction man-hours without a single lost-time incident on pharmaceutical projects alone.

Back